Christina Hendricks Kicks Off the LATISSE® Wishes Challenge with the Goal of Raising $500,000 for the Make-A-Wish Foundation®

Posted: July 3, 2011 at 3:48 pm

Christina Hendricks

Christina Hendricks Kicks Off the LATISSE® Wishes Challenge with the Goal of Raising $500,000 for the Make-A-Wish Foundation®

IRVINE, Calif. /PRNewswire/ — Allergan, Inc. (NYSE: AGN), the maker of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced the launch of the 2011 LATISSE® Wishes Challenge. Inspired by the tradition of blowing on an eyelash to make wishes come true, the campaign is gaining momentum for the second year by rallying women in support of the Make-A-Wish Foundation®, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® user and Emmy-nominated actress Christina Hendricks is encouraging women to join her to help raise $500,000 so a wish can be granted in every Make-A-Wish® chapter across the country. LATISSE® is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis).

Make-A-Wish Logo

Consumers can participate in the LATISSE® Wishes Challenge by donating a minimum of $20 to the Make-A-Wish Foundation through the campaign’s website, LATISSE® will double all donations up to $250,000 until November 30, 2011. In addition to helping the Make-A-Wish Foundation, the first 10,000 participants making the minimum donation will receive a LATISSE® free trial certificate, which they can take to a doctor to determine if LATISSE® is right for them. And, if participants invite two friends to join them in the campaign, they will also receive a $20 rebate off their next purchase of LATISSE®. Hendricks is also sharing her experience growing her lashes with LATISSE® throughout the campaign, since her doctor determined it is right for her.

“I’ve always felt my lashes were short and thin, and in my profession, I wear a lot of false lashes and makeup, which take a toll. So when LATISSE® became available, I was curious to learn more. My doctor talked with me about lashes, and I was surprised to learn that some women may notice their lashes thinning over time. Women who notice these changes in their lashes now have the option to talk to their doctor about LATISSE® and see if it’s right for them,” said Hendricks.

“LATISSE® is also a brand that contributes to children, and I couldn’t think of a better cause to support than the Make-A-Wish Foundation. When I was seven years old, I saw firsthand the difference a wish can make in the life of a child when a girl in my class got her wish to meet Erik Estrada.”

“The support generated by campaigns such as the LATISSE® Wishes Challenge has been invaluable in helping the Foundation grant the wishes of children nationwide,” said David Williams, Make-A-Wish Foundation of America president and chief executive officer. “For brave children like Isaac, who wished to meet a pirate and dig for buried treasure, and Sydney, who wished to swim like a mermaid in a lagoon in Bora Bora, a wish experience helps them feel stronger and more able to battle their illnesses. We encourage everyone to join the LATISSE® Wishes Challenge to help us grant the wishes of even more children and improve the quality of life for them and their families.”

“Allergan is proud to continue its commitment to the Make-A-Wish Foundation. In just two years, LATISSE® and the women across the country who use it have raised nearly $1.5 million to help the Make-A-Wish Foundation grant children’s wishes,” said David Pyott, Chairman of the Board, President and Chief Executive Officer of Allergan, Inc. “Women appreciate supporting a brand that gives back and that may also provide a solution for themselves. Through the LATISSE® Wishes Challenge, women will join Hendricks to support a wonderful cause and learn more about LATISSE® to see if it is right for them.”

Join the LATISSE® Wishes Challenge to support the Make-A-Wish Foundation and learn more about LATISSE® at Visit the website often to track the campaign’s progress in raising funds for the Make-A-Wish Foundation, learn more about some of the children whose wishes have been granted, follow Hendricks’ experience as she grows her lashes with LATISSE®, and upload your own LATISSE® lash photos. Please note that all photos are subject to approval before they can be shared in the gallery. You can also stay connected to the LATISSE® Wishes Challenge on Twitter via @WishesChallenge and on Facebook.

About the Make-A-Wish Foundation
The Make-A-Wish Foundation grants the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy. Founded in 1980 when a group of caring volunteers helped a young boy fulfill his dream of becoming a police officer, the Foundation is one of the world’s leading children’s charities, with 64 chapters in the United States and its territories. With the help of generous donors and nearly 25,000 volunteers, the Make-A-Wish Foundation grants a wish every 40 minutes and has granted more than 200,000 wishes in the United States. For more information about the Make-A-Wish Foundation, visit and discover how you can share the power of a wish®.

LATISSE® (bimatoprost ophthalmic solution) 0.03% is a prescription treatment for hypotrichosis used to grow eyelashes longer, fuller and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. The once-daily prescription treatment is applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. While individual results may vary, LATISSE® users may begin to notice longer lashes in about one month and experience full results in four months. If use of LATISSE® is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of several weeks to months (average eyelash hair cycle).

Similar to Allergan’s other medical aesthetic offerings, the benefits of LATISSE® are derived from scientific evidence, its quality formulation and medical origin. LATISSE® was clinically tested in a pivotal Phase III, multi-center, double-masked, placebo-controlled study to assess its safety and efficacy in patients with eyelash hypotrichosis, in which all endpoints (improved eyelash prominence, length, thickness and darkness) were met. Bimatoprost, the active ingredient in LATISSE®, was first approved in 2001 as a medical product to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension. Patients treated with bimatoprost for this specific eye condition experienced eyelash growth as a side effect. Given the existing and substantial clinical and post-marketing safety data with bimatoprost ophthalmic solution 0.03%, coupled with the positive results from the Phase III LATISSE® study, LATISSE® was approved by the FDA in December of 2008.

Allergan Logo

Allergan, Inc.

Source: Allergan

Related Post

Comments are closed.